SlideShare uma empresa Scribd logo
ARTIFICIAL BLOOD
Unit - 4
INTRODUCTION
● Blood is a body fluid in humans and other animals that delivers
necessary substances such as nutrients and oxygen to
the cells and transports metabolic waste products away from
those same cells.
● It is composed of blood cells suspended in blood plasma.
Plasma, which constitutes 55% of blood fluid, is mostly water
(92% by volume), and contains proteins, glucose,
mineral, ions, hormones, carbon dioxide and blood cells
themselves
Components of blood
Functions of blood
Artificial blood
● Artificial Blood (also called Blood Substitute or Blood Surrogate)
is a substance used to mimic and fulfill some functions of biological
blood. It aims to provide an alternative to blood transfusion, which is
transferring blood or blood based products from one person into
another.
● It does not contain plasma , RBCs or WBCs.
Need for artificial blood
● Natural blood must be stored at a cool temperature and it has a
short shelf life of only 42 days.
● Shortage of blood
● Immunological incompatibility
● Rare blood group demand
● Disease Transmission
● cost
Advantages of Artificial Blood
● Safe to use
● Compatible in the body- elimination of cross matching
● Oxygen carrying capacity, equally or surpassing that of
biological blood
● Pathogen and toxin free
● Minimal side effects
● Long shelf life
● Survivability over a wider range of storage temperatures
● Viscosity similar to Body blood
● No immunosuppression
● Cost efficient
BLOOD SUBSTITUENTS
● Blood substituents can serve as :-
○ Plasma volume expander
○ Replicate the oxygen carrying function of natural blood
● Plasma Expanders :- These are compounds, which are either entirely
synthetic or processed from natural proteins that serve as infusion
solutions which expand intravascular volume.
● RBC Substituents :- these are oxygen carriers but, differ the
way they carry .They are:-
○ Modified Hemoglobin
○ Perflurocarbons
PLATELET SUBSTITUENTS
● Platelet substituents have following properties:-
 Effective hemostasis with a significant duration of action
 No associated thrombogenicity
 No immunogenicity
 Sterility
 Long shelf life with simple storage requirements
 Easy preparation and administration
● Several different forms of platelet substitute are now under
development :
 Infusible Platelet Membranes (IPM)
 Thrombospheres
 lyophilized human platelets
PLATELET SUBSTITUENTS
RED BLOOD CELL SUBSTITUENTS
● Main function is to carry oxygen, as does natural hemoglobin.
● The use of oxygen-carrying blood substitutes is often called
Oxygen therapeutics to differentiate from true blood substitutes.
● The initial goal of oxygen carrying blood substitutes is merely to
mimic blood's oxygen transport capacity.
● There are two basic approaches to constructing an oxygen
therapeutics:
○ The first is perfluorocarbons (PFC), chemical compounds which
can carry and release oxygen. The specific PFC usually used is
either perfluorodecalin or dodecafluoropentane emulsion
(DDFPe).
○ The second approach is hemoglobin(HBOCs)
derived from humans, animals, or artificially via
recombinant technology, or via stem cell
production of red blood cells in vitro
Size of RBC SUBSTITUENTS
PERFLUOROCARBONS
● PFC are biologically inert materials that can dissolve
about 50 times more oxygen than blood plasma.
● they are relatively inexpensive to produce and can be
made devoid of any biological materials.
● Emulsion particles are 0.2 micron in diameter → Can
perfuse smallest capillaries, where no RBC flow.
● Not soluble in water, which means to get them to work
they must be combined with emulsions.
● They have the ability to carry much less oxygen than
haemoglobin based products.
STRUCTURE
● Perfluorocarbon core Surrounded by a phospholipid
surfactant that reduces the surface tension of the liquid in
which it is dissolved.
PRODUCTION PROCESS :-
● Water, salts, and phospholipids surfactant,
antibiotics,vitamins,nutrients are added and emulsified through
high-pressure homogenization.
● Purified through high temperatures of steam.
● Common PFCs:
○ Perfluorodecalin
○ Perfluoro octyl bromide(oxygent)
Generations of PFC
● 1st generation
○ FLUOSOL- DA 20%
○ Stored Frozen
○ Limited O2 carrying capacity.
○ Allergic reaction
○ It can deliver 0.4ml oxygen per 100ml blood
● 2nd generation
○ Oxygent 90%
○ Stored at 4’c
○ High O2 Carrying capacity
○ Oxygent can deliver upto 1.3 ml oxygen per
100 ml blood.
EXAMPLES OF PFC
● Fluosol-DA-20
Fluosol-DA-20, manufactured by Green Cross of Japan, was the
first and only oxygen-carrying blood substitute ever to receive
approval from the FDA. Although approved in 1989, it was withdrawn
in 1994 because it was cumbersome to administer to patients and it
had side effects.
● Oxygent
Oxygent, developed by Alliance Pharmaceutical Corporation in
San Diego, is a PFC-based oxygen carrier currently approved for
Phase II trials in both Europe and the United States. Oxygent initially
showed promise for decreasing the need for donated blood during
surgery. However, phase III trials were stopped recently because
patients receiving Oxygent showed a higher risk of
stroke compared to controls receiving donor blood.
● Perftoran
Perftoran, sponsored by Moscow, Russia, is a PFC emulsion
approved for human use in Russia in 1996. In 2005, the same drug
was registered and approved as an authorized blood substitute for
use in Mexico under the trade name Perftec, distributed by KEM
Laboratory in Mexico.
● PHER-O2
PHER-O2, developed by Sanguine Corporation in Pasadena, CA,
is a PFC with oxygen-carrying capabilities and reportedly few side
effects. This drug is now under evaluation not only as a blood
substitute for transfusion, but also as a therapy for heart attack and
stroke.
PERFTORAN
Advantage of PFC
● Do not react with oxygen
● Inexpensive
● Allow easy transportation of the oxygen to the body
● They allow increased solubility of oxygen in plasma
● minimize the effects of factors like pH and temperature in
blood circulation.
Disadvantages of PFC
● Often causes flu-like symptoms
● Unable to remain mixed as aqueous solutions
● A decrease in blood platelet count.
● PFC products cannot be used by the human body, and must be
discarded.
● PFCs absorb oxygen passively, patients must breathe at a
linear rate to ensure oxygenation of tissues.
● The problem with Fluosal-DA was that they dissolve less
oxygen than pure liquids
HAEMOGLOBIN BASED OXYGEN CARRIERS
● Hemoglobin-based Oxygen Carriers(HBOC) were created as a
mechanism to mimic the oxygen-carrying role of hemoglobin in
the body, while still reducing the need for real human
hemoglobin.
● HBOCs are manufactured from sterilized hemoglobin and look
somewhat like real blood.
● These dark red colored blood substitutes are often made from
RBCs of expired human blood, cow blood, hemoglobin-
producing genetically modified bacteria, or human placentas.
● Through a chemical process called polymerization, two or more
three molecules bonded together to form a larger
HBOC molecule.
● HBOCs are smaller than natural RBCs. While natural
RBCs remain in the bloodstream for about 100 days,
HBOCs circulate in human blood for only a day.
● SIDE EFFECTS OF HBOC
elevated blood pressure,
abdominal discomfort,
a temporary reddish coloration of the eyes or skin.
PRODUCTION PROCESS
● HB synthesis
○ Synthetically produced Hb: E.coli(P678-54)
○ Isolated Hb: human or animal blood(bovine blood)
● Seed Tank
● Fermentation
● Final processing
EXAMPLES OF HBOC
● PolyHeme
○ PolyHeme, sponsored by Northfield Laboratories in Chicago, is a
first-generation polymerized hemoglobin-based oxygen-carrying
hemoglobin solution. In the mid-2000s Polyheme was compared
with donor blood in a clinical trial of more than 700 people in a US
Phase III Trial.
○ Patients receiving Polyheme had a slightly higher rate of negative
side effects such as high blood pressure, inflammation, and
multiple organ failure compared with the control group. (The small
size of the PolyHeme molecule causes it to bind with nitric oxide,
leading to constricted blood vessels).
● Hemotech
○ Hemotech, produced by HemoBiotech in Dallas, TX, is
a proprietary, chemically modified hemoglobin
manufactured from cow blood. It was originally
developed in 1985. With a shelf life of more than six
months, if has shown no signs of toxicity in clinical
studies. Hemotech is currently approved by the FDA
for Phase I trials in the United States.
Advantage of HBOC
● Available in much larger quantities.
● Can be stored for long durations.
● Can be administered rapidly without typing or cross
matching blood types.
● Can be sterilized via pasteurization.
Disadvantage of HBOC
● Short half-life
● Disrupts certain physiological structures, especially the
gastrointestinal tract and normal red blood cell
haemoglobin.
● They release free radicals into the body
● Availability and cost
APPLICATIONS OF ARTIFICIAL BLOOD
● Blood substitutes :
○ hemorrhagic shock; hemorrhage (war, surgery); anemia.
○ Whole-body rinse out : acute drug intoxication; acute hepatic
failure.
○ Local Ischemia : acute Myocardial infection ; cardiac failure;
○ brain infarction; acute arterial thrombosis and embolism.
○ General Ischemia : CO intoxication.
○ Aid for organ recovery : acute renal failure; acute hepatic failure ;
acute pancreatitis.
○ radiotherapy; chemotherapy.
THANK YOU

Mais conteúdo relacionado

Mais procurados

Artificial blood..a tool for new life
Artificial blood..a tool for new lifeArtificial blood..a tool for new life
Artificial blood..a tool for new life
JYOTI DEVENDRA
 
Blood components preparation and therapeutic uses final
Blood components preparation and therapeutic uses finalBlood components preparation and therapeutic uses final
Blood components preparation and therapeutic uses final
globalsoin
 

Mais procurados (20)

Artificial blood..a tool for new life
Artificial blood..a tool for new lifeArtificial blood..a tool for new life
Artificial blood..a tool for new life
 
Artificial Blood Substitutes
Artificial Blood SubstitutesArtificial Blood Substitutes
Artificial Blood Substitutes
 
Red cell substitute
Red cell substituteRed cell substitute
Red cell substitute
 
Blood substitues
Blood substituesBlood substitues
Blood substitues
 
ppt - artificial blood.pptx
ppt - artificial blood.pptxppt - artificial blood.pptx
ppt - artificial blood.pptx
 
Blood components
Blood componentsBlood components
Blood components
 
Blood substitutes in therapy
Blood substitutes in therapyBlood substitutes in therapy
Blood substitutes in therapy
 
Red cell and platelet storage lesions and their effect in transfusion practise
Red cell and platelet storage lesions and their effect in transfusion practiseRed cell and platelet storage lesions and their effect in transfusion practise
Red cell and platelet storage lesions and their effect in transfusion practise
 
update on blood product alternatives
update on blood product alternativesupdate on blood product alternatives
update on blood product alternatives
 
Use of Blood Components in Clinical Practice - Part 1
Use of Blood Components in Clinical Practice - Part 1Use of Blood Components in Clinical Practice - Part 1
Use of Blood Components in Clinical Practice - Part 1
 
blood banking ..Preparation of blood components and their therapeutic uses
blood banking ..Preparation of blood components and their therapeutic usesblood banking ..Preparation of blood components and their therapeutic uses
blood banking ..Preparation of blood components and their therapeutic uses
 
Component prep and therapy
Component prep and therapyComponent prep and therapy
Component prep and therapy
 
Anticoagulants and blood preservatives
Anticoagulants and blood preservativesAnticoagulants and blood preservatives
Anticoagulants and blood preservatives
 
Blood components preparation and therapeutic uses final
Blood components preparation and therapeutic uses finalBlood components preparation and therapeutic uses final
Blood components preparation and therapeutic uses final
 
Blood Components 101
Blood Components 101Blood Components 101
Blood Components 101
 
Autologous Blood Transfusion
Autologous Blood TransfusionAutologous Blood Transfusion
Autologous Blood Transfusion
 
Storage,preservation, and transportation of blood.pptx
Storage,preservation, and transportation of blood.pptxStorage,preservation, and transportation of blood.pptx
Storage,preservation, and transportation of blood.pptx
 
Lecture on Blood component therapy
Lecture on Blood component therapyLecture on Blood component therapy
Lecture on Blood component therapy
 
Blood components
Blood componentsBlood components
Blood components
 
33. use of blood products
33. use of blood products33. use of blood products
33. use of blood products
 

Semelhante a Artificial blood - PFC & HBOC

Transfusion Medicine Ticu
Transfusion Medicine TicuTransfusion Medicine Ticu
Transfusion Medicine Ticu
Dang Thanh Tuan
 
BLOOD physiology and pathology slides ppt
BLOOD physiology and pathology slides pptBLOOD physiology and pathology slides ppt
BLOOD physiology and pathology slides ppt
richanaina28
 

Semelhante a Artificial blood - PFC & HBOC (20)

PRASANKA ROUT.pptx
PRASANKA ROUT.pptxPRASANKA ROUT.pptx
PRASANKA ROUT.pptx
 
BB 1 preflurochemical BS.pptx
BB 1 preflurochemical BS.pptxBB 1 preflurochemical BS.pptx
BB 1 preflurochemical BS.pptx
 
ARTIFICIAL BLOOD presentation to to.pptx
ARTIFICIAL BLOOD presentation to to.pptxARTIFICIAL BLOOD presentation to to.pptx
ARTIFICIAL BLOOD presentation to to.pptx
 
The blood
The bloodThe blood
The blood
 
Transfusion Medicine
Transfusion MedicineTransfusion Medicine
Transfusion Medicine
 
Transfusion Medicine Ticu
Transfusion Medicine TicuTransfusion Medicine Ticu
Transfusion Medicine Ticu
 
Blood
BloodBlood
Blood
 
Intravenous fluids
Intravenous fluidsIntravenous fluids
Intravenous fluids
 
BLOOD COMPONENTS.pptx
BLOOD COMPONENTS.pptxBLOOD COMPONENTS.pptx
BLOOD COMPONENTS.pptx
 
Hemoglobin based artificial oxygen carrier
Hemoglobin based artificial oxygen carrierHemoglobin based artificial oxygen carrier
Hemoglobin based artificial oxygen carrier
 
OXYGEN AS A DRUG.pptx
OXYGEN AS A DRUG.pptxOXYGEN AS A DRUG.pptx
OXYGEN AS A DRUG.pptx
 
blood physiology
blood physiologyblood physiology
blood physiology
 
Blood part 1
Blood part 1Blood part 1
Blood part 1
 
Plasma volume expanders
Plasma volume expandersPlasma volume expanders
Plasma volume expanders
 
Blood
Blood Blood
Blood
 
Blood and Blood related disorders
Blood and Blood related disordersBlood and Blood related disorders
Blood and Blood related disorders
 
BLOOD physiology and pathology slides ppt
BLOOD physiology and pathology slides pptBLOOD physiology and pathology slides ppt
BLOOD physiology and pathology slides ppt
 
Anticoagulants
AnticoagulantsAnticoagulants
Anticoagulants
 
unit-3 blood product B.Pharma 3rd year .pptx
unit-3 blood product B.Pharma 3rd year .pptxunit-3 blood product B.Pharma 3rd year .pptx
unit-3 blood product B.Pharma 3rd year .pptx
 
Plasma volume expanders
Plasma volume expandersPlasma volume expanders
Plasma volume expanders
 

Último

THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
DR SETH JOTHAM
 
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
MedicoseAcademics
 

Último (20)

Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptxANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
 
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptx
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
 
Is preeclampsia and spontaneous preterm delivery associate with vascular and ...
Is preeclampsia and spontaneous preterm delivery associate with vascular and ...Is preeclampsia and spontaneous preterm delivery associate with vascular and ...
Is preeclampsia and spontaneous preterm delivery associate with vascular and ...
 
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
 
Compare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from homeCompare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from home
 
End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feel
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
 
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptxMALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
 
Creating Accessible Public Health Communications
Creating Accessible Public Health CommunicationsCreating Accessible Public Health Communications
Creating Accessible Public Health Communications
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgery
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
 
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.
 
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDFNCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
 

Artificial blood - PFC & HBOC

  • 2. INTRODUCTION ● Blood is a body fluid in humans and other animals that delivers necessary substances such as nutrients and oxygen to the cells and transports metabolic waste products away from those same cells. ● It is composed of blood cells suspended in blood plasma. Plasma, which constitutes 55% of blood fluid, is mostly water (92% by volume), and contains proteins, glucose, mineral, ions, hormones, carbon dioxide and blood cells themselves
  • 5. Artificial blood ● Artificial Blood (also called Blood Substitute or Blood Surrogate) is a substance used to mimic and fulfill some functions of biological blood. It aims to provide an alternative to blood transfusion, which is transferring blood or blood based products from one person into another. ● It does not contain plasma , RBCs or WBCs.
  • 6. Need for artificial blood ● Natural blood must be stored at a cool temperature and it has a short shelf life of only 42 days. ● Shortage of blood ● Immunological incompatibility ● Rare blood group demand ● Disease Transmission ● cost
  • 7. Advantages of Artificial Blood ● Safe to use ● Compatible in the body- elimination of cross matching ● Oxygen carrying capacity, equally or surpassing that of biological blood ● Pathogen and toxin free ● Minimal side effects ● Long shelf life ● Survivability over a wider range of storage temperatures ● Viscosity similar to Body blood ● No immunosuppression ● Cost efficient
  • 8. BLOOD SUBSTITUENTS ● Blood substituents can serve as :- ○ Plasma volume expander ○ Replicate the oxygen carrying function of natural blood ● Plasma Expanders :- These are compounds, which are either entirely synthetic or processed from natural proteins that serve as infusion solutions which expand intravascular volume. ● RBC Substituents :- these are oxygen carriers but, differ the way they carry .They are:- ○ Modified Hemoglobin ○ Perflurocarbons
  • 9. PLATELET SUBSTITUENTS ● Platelet substituents have following properties:-  Effective hemostasis with a significant duration of action  No associated thrombogenicity  No immunogenicity  Sterility  Long shelf life with simple storage requirements  Easy preparation and administration ● Several different forms of platelet substitute are now under development :  Infusible Platelet Membranes (IPM)  Thrombospheres  lyophilized human platelets
  • 11. RED BLOOD CELL SUBSTITUENTS ● Main function is to carry oxygen, as does natural hemoglobin. ● The use of oxygen-carrying blood substitutes is often called Oxygen therapeutics to differentiate from true blood substitutes. ● The initial goal of oxygen carrying blood substitutes is merely to mimic blood's oxygen transport capacity. ● There are two basic approaches to constructing an oxygen therapeutics: ○ The first is perfluorocarbons (PFC), chemical compounds which can carry and release oxygen. The specific PFC usually used is either perfluorodecalin or dodecafluoropentane emulsion (DDFPe). ○ The second approach is hemoglobin(HBOCs) derived from humans, animals, or artificially via recombinant technology, or via stem cell production of red blood cells in vitro
  • 12. Size of RBC SUBSTITUENTS
  • 13. PERFLUOROCARBONS ● PFC are biologically inert materials that can dissolve about 50 times more oxygen than blood plasma. ● they are relatively inexpensive to produce and can be made devoid of any biological materials. ● Emulsion particles are 0.2 micron in diameter → Can perfuse smallest capillaries, where no RBC flow. ● Not soluble in water, which means to get them to work they must be combined with emulsions. ● They have the ability to carry much less oxygen than haemoglobin based products.
  • 14. STRUCTURE ● Perfluorocarbon core Surrounded by a phospholipid surfactant that reduces the surface tension of the liquid in which it is dissolved.
  • 15. PRODUCTION PROCESS :- ● Water, salts, and phospholipids surfactant, antibiotics,vitamins,nutrients are added and emulsified through high-pressure homogenization. ● Purified through high temperatures of steam. ● Common PFCs: ○ Perfluorodecalin ○ Perfluoro octyl bromide(oxygent)
  • 16. Generations of PFC ● 1st generation ○ FLUOSOL- DA 20% ○ Stored Frozen ○ Limited O2 carrying capacity. ○ Allergic reaction ○ It can deliver 0.4ml oxygen per 100ml blood ● 2nd generation ○ Oxygent 90% ○ Stored at 4’c ○ High O2 Carrying capacity ○ Oxygent can deliver upto 1.3 ml oxygen per 100 ml blood.
  • 17. EXAMPLES OF PFC ● Fluosol-DA-20 Fluosol-DA-20, manufactured by Green Cross of Japan, was the first and only oxygen-carrying blood substitute ever to receive approval from the FDA. Although approved in 1989, it was withdrawn in 1994 because it was cumbersome to administer to patients and it had side effects. ● Oxygent Oxygent, developed by Alliance Pharmaceutical Corporation in San Diego, is a PFC-based oxygen carrier currently approved for Phase II trials in both Europe and the United States. Oxygent initially showed promise for decreasing the need for donated blood during surgery. However, phase III trials were stopped recently because patients receiving Oxygent showed a higher risk of stroke compared to controls receiving donor blood.
  • 18. ● Perftoran Perftoran, sponsored by Moscow, Russia, is a PFC emulsion approved for human use in Russia in 1996. In 2005, the same drug was registered and approved as an authorized blood substitute for use in Mexico under the trade name Perftec, distributed by KEM Laboratory in Mexico. ● PHER-O2 PHER-O2, developed by Sanguine Corporation in Pasadena, CA, is a PFC with oxygen-carrying capabilities and reportedly few side effects. This drug is now under evaluation not only as a blood substitute for transfusion, but also as a therapy for heart attack and stroke.
  • 20. Advantage of PFC ● Do not react with oxygen ● Inexpensive ● Allow easy transportation of the oxygen to the body ● They allow increased solubility of oxygen in plasma ● minimize the effects of factors like pH and temperature in blood circulation.
  • 21. Disadvantages of PFC ● Often causes flu-like symptoms ● Unable to remain mixed as aqueous solutions ● A decrease in blood platelet count. ● PFC products cannot be used by the human body, and must be discarded. ● PFCs absorb oxygen passively, patients must breathe at a linear rate to ensure oxygenation of tissues. ● The problem with Fluosal-DA was that they dissolve less oxygen than pure liquids
  • 22. HAEMOGLOBIN BASED OXYGEN CARRIERS ● Hemoglobin-based Oxygen Carriers(HBOC) were created as a mechanism to mimic the oxygen-carrying role of hemoglobin in the body, while still reducing the need for real human hemoglobin. ● HBOCs are manufactured from sterilized hemoglobin and look somewhat like real blood. ● These dark red colored blood substitutes are often made from RBCs of expired human blood, cow blood, hemoglobin- producing genetically modified bacteria, or human placentas. ● Through a chemical process called polymerization, two or more three molecules bonded together to form a larger HBOC molecule.
  • 23. ● HBOCs are smaller than natural RBCs. While natural RBCs remain in the bloodstream for about 100 days, HBOCs circulate in human blood for only a day. ● SIDE EFFECTS OF HBOC elevated blood pressure, abdominal discomfort, a temporary reddish coloration of the eyes or skin.
  • 24.
  • 25. PRODUCTION PROCESS ● HB synthesis ○ Synthetically produced Hb: E.coli(P678-54) ○ Isolated Hb: human or animal blood(bovine blood) ● Seed Tank ● Fermentation ● Final processing
  • 27. ● PolyHeme ○ PolyHeme, sponsored by Northfield Laboratories in Chicago, is a first-generation polymerized hemoglobin-based oxygen-carrying hemoglobin solution. In the mid-2000s Polyheme was compared with donor blood in a clinical trial of more than 700 people in a US Phase III Trial. ○ Patients receiving Polyheme had a slightly higher rate of negative side effects such as high blood pressure, inflammation, and multiple organ failure compared with the control group. (The small size of the PolyHeme molecule causes it to bind with nitric oxide, leading to constricted blood vessels).
  • 28. ● Hemotech ○ Hemotech, produced by HemoBiotech in Dallas, TX, is a proprietary, chemically modified hemoglobin manufactured from cow blood. It was originally developed in 1985. With a shelf life of more than six months, if has shown no signs of toxicity in clinical studies. Hemotech is currently approved by the FDA for Phase I trials in the United States.
  • 29. Advantage of HBOC ● Available in much larger quantities. ● Can be stored for long durations. ● Can be administered rapidly without typing or cross matching blood types. ● Can be sterilized via pasteurization.
  • 30. Disadvantage of HBOC ● Short half-life ● Disrupts certain physiological structures, especially the gastrointestinal tract and normal red blood cell haemoglobin. ● They release free radicals into the body ● Availability and cost
  • 31. APPLICATIONS OF ARTIFICIAL BLOOD ● Blood substitutes : ○ hemorrhagic shock; hemorrhage (war, surgery); anemia. ○ Whole-body rinse out : acute drug intoxication; acute hepatic failure. ○ Local Ischemia : acute Myocardial infection ; cardiac failure; ○ brain infarction; acute arterial thrombosis and embolism. ○ General Ischemia : CO intoxication. ○ Aid for organ recovery : acute renal failure; acute hepatic failure ; acute pancreatitis. ○ radiotherapy; chemotherapy.